Given that this subset of cancers are typically resistant to standard-of-care platinum chemotherapy and associated with poor overall survival, we sought to address this clinical unmet need by identifying a treatment strategy that targets critical survival pathways for CCNE1-driven cancers5,6. Here, CCNE1 is linked to cancer.